{"entity":{"id":"nct07026279","kind":"trial","name":"A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer","aka":[],"tldr":"A phase 1/2 trial of narmafotinib ascending doses in pancreatic ductal adenocarcinoma, run by Amplia Therapeutics Limited, active and no longer recruiting.","summary":"A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer is a phase 1/2 interventional study registered as NCT07026279 by Amplia Therapeutics Limited, with 67 participants enrolled, started 2025-08-18 and due to reach its primary completion in 2029-07. Interventions recorded: narmafotinib ascending doses and narmafotinib dose comparison.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07026279","url":"https://clinicaltrials.gov/study/NCT07026279"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07026279","phase":"1/2","setting":"A Phase 1b/2a, Multicenter, Open Label Study of the Safety, Efficacy and Pharmacokinetics of Narmafotinib in Combination With Modified FOLFIRINOX in Pancreatic Cancer Patients","sponsor":"Amplia Therapeutics Limited","enrolled":67,"outcomes":[]},"route":"/trials/nct07026279/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}]}}